College of Cardiology. Nov 7 2017;70(19):2389-2392. doi:10.1016/j.jacc.2017.09.031
181. Bayés-Genis A, González A, Lupón J. ST2 in Heart Failure. Circ Heart Fail. Dec 2018;11(12):e005582. doi:10.1161/circheartfailure.118.005582
182. Dattagupta A, Immaneni S. ST2: Current status. Indian Heart J. Jul 2018;70 Suppl 1(Suppl 1):S96-s101. doi:10.1016/j.ihj.2018.03.001
183. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Journal of the American College of Cardiology. Dec 16 2008;52(25):2166-74. doi:10.1016/j.jacc.2008.09.027
184. Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. Jul 2013;60(100):16-26. doi:10.1016/j.yjmcc.2013.03.020
185. Pascual-Figal DA, Pérez-Martínez MT, Asensio-Lopez MC, et al. Pulmonary Production of Soluble ST2 in Heart Failure. Circ Heart Fail. Dec 2018;11(12):e005488. doi:10.1161/circheartfailure.118.005488
186. Kuroiwa K, Li H, Tago K, et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma. Apr 2000;19(2):151-9. doi:10.1089/02724570050031194
187. Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. Clin Chim Acta. Oct 9 2012;413(19-20):1493-4. doi:10.1016/j.cca.2012.06.021
188. Mueller T, Dieplinger B. The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn. Jan 2013;13(1):13-30. doi:10.1586/erm.12.128
Có thể bạn quan tâm!
-
Phối Hợp Với Các Yếu Tố Lâm Sàng -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 19 -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 20 -
Thông Tin Về Nghiên Cứu Mục Đích Và Tiến Hành Nghiên Cứu -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 23 -
Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 24
Xem toàn bộ 193 trang tài liệu này.
189. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem. Jun 2010;43(9):714-9. doi:10.1016/j.clinbiochem.2010.02.002
190. Januzzi JL, Jr., Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro- Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Journal of the American College of Cardiology. Aug 14 2007;50(7):607-13. doi:10.1016/j.jacc.2007.05.014
191. Pascual-Figal DA, Ordođez-Llanos J, Tornel PL, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Journal of the American College of Cardiology. Dec 1 2009;54(23):2174-9. doi:10.1016/j.jacc.2009.07.041
192. Aimo A, Vergaro G, Passino C, et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. JACC Heart failure. Apr 2017;5(4):280-286. doi:10.1016/j.jchf.2016.09.010
193. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. Apr 2008;54(4):752-6. doi:10.1373/clinchem.2007.096560
194. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review.
Future Cardiol. Jul 2014;10(4):525-39. doi:10.2217/fca.14.36
195. Villacorta H, Maisel AS. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. Feb 2016;106(2):145-52. doi:10.5935/abc.20150151
196. Bahuleyan CG, Alummoottil GK, Abdullakutty J, et al. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study. Indian Heart J. Jul 2018;70 Suppl 1(Suppl 1):S79-s84. doi:10.1016/j.ihj.2017.09.010
197. Gül İ, Yücel O, Zararsız A, et al. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatol J Cardiol. Sep 2017;18(3):200-205. doi:10.14744/AnatolJCardiol.2017.7741
198. Kuster N, Huet F, Dupuy AM, et al. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure. ESC Heart Fail. Oct 2020;7(5):2230-2239. doi:10.1002/ehf2.12680
199. Emdin M, Aimo A, Vergaro G, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. Nov 6 2018;72(19):2309-2320. doi:10.1016/j.jacc.2018.08.2165
200. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. Mar 2011;4(2):180-7. doi:10.1161/circheartfailure.110.958223
201. Dalal JJ, Digrajkar A, Das B, Bansal M, Toomu A, Maisel AS. ST2 elevation in heart failure, predictive of a high early mortality. Indian Heart J. Nov-Dec 2018;70(6):822-827. doi:10.1016/j.ihj.2018.08.019
202. Grande D, Leone M, Rizzo C, et al. A Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart
Failure Outpatients. J Cardiovasc Dev Dis. Jul 15
2017;4(3)doi:10.3390/jcdd4030009
203. Gruson D, Ferracin B, Ahn SA, Rousseau MF. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. International journal of cardiology. Jun 15
2015;189:185-7. doi:10.1016/j.ijcard.2015.04.074
204. Wojtczak-Soska K, Sakowicz A, Pietrucha T, Janikowski K, Lelonek M. Soluble ST2 protein and hospitalizations due to worsening chronic heart failure during a one-year follow-up in a population with reduced ejection fraction. Adv Clin Exp Med. Sep 2017;26(6):931-938. doi:10.17219/acem/63005
205. Yucel O, Gul I, Zararsiz A, et al. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz. Aug 2018;43(5):455-460. Zusammenhang zwischen löslichem ST2 und funktioneller Kapazität bei ambulant versorgten Herzinsuffizienzpatienten. doi:10.1007/s00059-017-4590-1
206. Traxler D, Zimmermann M, Simader E, et al. The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. Clin Chim Acta. Nov 2020;510:507-514. doi:10.1016/j.cca.2020.07.050
207. Ventoulis I, Mantziari L, Mouratoglou SA, et al. NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scand Cardiovasc J. Aug 2015;49(4):213-9. doi:10.3109/14017431.2015.1043141
208. Dong G, Chen H, Zhang H, Gu Y. Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiology. Apr 26 2021:1-8. doi:10.1159/000509660
209. Aimo A, Januzzi JL, Jr., Vergaro G, et al. Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro- B-type natriuretic peptide and high-sensitivity troponin T. European journal of heart failure. Nov 2020;22(11):2078-2088. doi:10.1002/ejhf.1701
210. Kurlianskaya EK, Mrochek AG, Denisevich TL, Kaliadka MG, Russkich, II. [The Prognostic Role of Biomarkers in Patients With Chronic Heart Failure]. Kardiologiia. Feb 4 2020;60(1):16-22. doi:10.18087/cardio.2020.1.n882
211. Aimo A, Januzzi JL, Jr., Bayes-Genis A, et al. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology. Oct 29 2019;74(17):2193-2203. doi:10.1016/j.jacc.2019.08.1039
212. Barutaut M, Fournier P, Peacock WF, et al. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiol. Dec 2020;75(8):739-747. doi:10.1080/00015385.2019.1669847
213. Nguyễn Hữu Ngọc, Nguyễn Tri Thức, Nguyễn Hữu Thịnh, Lý Thụy Đoan Trinh, Lý Văn Chiêu, Huỳnh Văn Minh. Nghiên cứu nồng độ sST2 ở bệnh nhân tăng huyết áp nguyên phát. Tạp chí Tim Mạch học Việt Nam. 2017;80:61-70.
214. Trần Thị Thanh Trúc, Hoàng Anh Tiến, Võ Thành Nhân. Nghiên cứu sự kết hợp sST2 và BNP huyết thanh trong tiên lượng suy tim và tử vong trong 30 ngày ở bệnh nhân nhồi máu cơ tim cấp ST chênh lên. Tạp chí Y Dược học. 2016;6(02)(02):61.
215. Phạm Nguyễn Vinh, Huỳnh Thanh Kiều, Jannuzzi J.L, Nguyễn Ngô Thanh Phương, Hồ Thị Tuyết Mai. Nghiên cứu về sST2 trong suy tim cấp ở người Việt Nam. Chuyên đề Tim Mạch học. 2018;
216. Shahar E, Lee S, Kim J, Duval S, Barber C, Luepker RV. Hospitalized heart failure: rates and long-term mortality. J Card Fail. Oct 2004;10(5):374-9. doi:10.1016/j.cardfail.2004.02.003
217. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Journal of the American College of Cardiology. Jul 28 2015;66(4):403-69. doi:10.1016/j.jacc.2014.12.018
218. Consultation; WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. Jan 10 2004;363(9403):157-63. doi:10.1016/s0140-6736(03)15268-3
219. Huỳnh Văn Minh, Trần Văn Huy, Phạm Gia Khải. Khuyến cáo về chẩn đoán, điều trị và dự phòng tăng huyết áp 2015. Hội tim mạch học quốc gia Việt Nam; 2015.
220. Đặng Vạn Phước, Phạm Gia Khải, Nguyễn Lân Việt. Khuyến cáo về chẩn
đoán và điều trị rối loạn Lipid máu. Hội tim mạch học quốc gia Việt Nam; 2016.
221. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. Dec 17 2002;106(25):3143-421.
222. American Diabetes Association. Standards of medical care in diabetes--2012. 2012/01/04 ed. Diabetes Care, 35 (1); 2012.
223. Arora P, Rajagopalan S, Patel N, Nainani N, Venuto RC, Lohr JW. The MDRD equation underestimates the prevalence of CKD among blacks and overestimates the prevalence of CKD among whites compared to the CKD-EPI equation: a retrospective cohort study. BMC Nephrol. Jan 20 2012;13:4. doi:10.1186/1471-2369-13-4
224. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice
guideline. Ann Intern Med. Jun 4 2013;158(11):825-30. doi:10.7326/0003-4819-158- 11-201306040-00007
225. World Health Organization. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011;
226. Phạm Quốc Khánh, Nguyễn Lân Việt, Đặng Vạn Phước. Khuyến cáo về chẩn
đoán và điều trị rung nhĩ. Hội tim mạch học quốc gia Việt Nam; 2016.
227. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. Oct 2010;12(10):1360-420. doi:10.1093/europace/euq350
228. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. Mar 2015;16(3):233-70. doi:10.1093/ehjci/jev014
229. Nguyễn Ngọc Thanh Vân, Nguyễn Đinh Quốc Anh, Hoàng Văn Sỹ, Châu Ngọc Hoa. Khảo sát điều trị suy tim theo khuyến cáo của hội tim Châu Âu 2016. Y Học Thành Phố Hồ Chí Minh. 2021;25(2):35-41.
230. Nguyễn Văn Yêm, Châu Ngọc Hoa, Phạm Nguyễn Vinh. Tính an toàn và hiệu quả của máy tạo nhịp tái đồng bộ tim trong điều trị suy tim kháng trị với thuốc. Tạp chí Y học Thành phố Hồ Chí Minh. 2020;24(3):260 - 268.
231. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. International journal of cardiology. 2014;172(1):e250-2. doi:10.1016/j.ijcard.2013.12.101
232. Greiser KH, Kluttig A, Schumann B, et al. Cardiovascular disease, risk factors and heart rate variability in the elderly general population: design and objectives of the CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. BMC cardiovascular disorders. Nov 11 2005;5:33. doi:10.1186/1471-2261-5-33
233. Xu SD, Su GH, Lu YX, et al. Elevated soluble ST2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure. Int Heart J. 2014;55(5):445-50. doi:10.1536/ihj.13-371
234. Nguyễn Dương Khang, Châu Ngọc Hoa. Nghiệm pháp đi bộ 6 phút trước xuất viện và tỉ lệ tái nhập viện trong vòng 30 ngày ở bệnh nhân suy tim. Tạp chí Y Học Thành phố Hồ Chí Minh. 2021;25(2):42-47.
235. Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol. Dec 2020;27(2_suppl):27-34. doi:10.1177/2047487320960288
236. World Health Organization. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. Oct 17 2020;396(10258):1223-1249. doi:10.1016/s0140- 6736(20)30752-2
237. Sharma A, Zhao X, Hammill BG, et al. Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. Circ Heart Fail. Jun 2018;11(6):e004646. doi:10.1161/circheartfailure.117.004646
238. Ikama MS, Nsitou BM, Kocko I, Mongo NS, Kimbally-Kaky G, Nkoua JL. Prevalence of anaemia among patients with heart failure at the Brazzaville University Hospital. Cardiovasc J Afr. May-Jun 2015;26(3):140-2. doi:10.5830/cvja-2015-021
239. Vũ Hoàng Vũ, Đặng Vạn Phước. Giá trị của NT-proBNP (N-terminal B-type natriuretic peptide) trong chẩn đoán suy tim. Tạp chí Y Học Thành phố Hồ Chí Minh. 2009;13(1):1-5.
240. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro- brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. European heart journal. Oct 2003;24(19):1735-43. doi:10.1016/j.ehj.2003.07.005
241. Verdú JM, Comín-Colet J, Domingo M, et al. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol (Engl Ed). Jul 2012;65(7):613-9. doi:10.1016/j.recesp.2012.01.019
242. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. European journal of heart failure. Jun 2005;7(4):537-41. doi:10.1016/j.ejheart.2005.01.022
243. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. European heart journal. Feb 2006;27(3):330-7. doi:10.1093/eurheartj/ehi631
244. Januzzi JL, Jr. Camargo, C. A. Anwaruddin, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. Apr 15 2005;95(8):948-54. doi:10.1016/j.amjcard.2004.12.032
245. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. Feb 11 2003;107(5):721-6. doi:10.1161/01.cir.0000047274.66749.fe
246. Rehman SU, Mueller T, Januzzi JL, Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology. Oct 28 2008;52(18):1458-65. doi:10.1016/j.jacc.2008.07.042
247. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. Jan 15 2011;107(2):259-67. doi:10.1016/j.amjcard.2010.09.011
248. Wang Y, Zhou Q, An T, et al. Reference value and clinical correlates of soluble ST2 in healthy community-based Chinese population. Zhonghua Xin Xue Guan Bing Za Zhi. Oct 2015;43(10):900-3.
249. Aimo A, Januzzi JL, Jr., Vergaro G, et al. Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. Eur J Prev Cardiol. Nov 2019;26(16):1751-1759. doi:10.1177/2047487319852809
250. Dimitropoulos S, Mystakidi VC, Oikonomou E, et al. Association of Soluble Suppression of Tumorigenesis-2 (ST2) with Endothelial Function in Patients with Ischemic Heart Failure. Int J Mol Sci. Dec 9 2020;21(24)doi:10.3390/ijms21249385
251. Alonso N, Lupón J, Barallat J, et al. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol. Nov 3 2016;15(1):151. doi:10.1186/s12933-016-0470-x
252. Tan ESJ, Chan SP, Liew OW, et al. Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clin Chem. Jan 8 2021;67(1):216-226. doi:10.1093/clinchem/hvaa287
253. Chen C, Qu X, Gao Z, et al. Soluble ST2 in Patients with Nonvalvular Atrial Fibrillation and Prediction of Heart Failure. Int Heart J. Jan 27 2018;59(1):58-63. doi:10.1536/ihj.16-520
254. Di Tanna GL, Wirtz H, Burrows KL, Globe G. Evaluating risk prediction models for adults with heart failure: A systematic literature review. PLoS One. 2020;15(1):e0224135. doi:10.1371/journal.pone.0224135
255. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart failure. Oct 2014;2(5):440-6. doi:10.1016/j.jchf.2014.04.008
256. Lau K, Malik A, Foroutan F, et al. Resting Heart Rate as an Important Predictor of Mortality and Morbidity in Ambulatory Patients With Heart Failure: A Systematic Review and Meta-Analysis. J Card Fail. Mar 2021;27(3):349-363. doi:10.1016/j.cardfail.2020.11.003
257. Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis. International journal of cardiology. Oct 1 2015;196:98-106. doi:10.1016/j.ijcard.2015.05.180
258. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little, Brown & Co; 1994.